56. Behcet disease Clinical trials / Disease details
Clinical trials : 81 / Drugs : 107 - (DrugBank : 30) / Drug target genes : 36 - Drug target pathways : 116
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-011237-27-FR (EUCTR) | 23/10/2009 | 06/08/2009 | A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy | A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy | Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease MedDRA version: 12.0;Level: LLT;Classification code 10033687;Term: Panuveitis MedDRA version: 12.0;Classification code 10036370;Term: Posterior uveitis | Product Name: AIN457 Product Code: AIN457 INN or Proposed INN: Not available Other descriptive name: rhumAb to Il-17A (IgG1-k-class) | Novartis Pharma Services Ag | NULL | Not Recruiting | Female: yes Male: yes | 102 | France;Hungary;Greece;Spain;Austria;Germany;Italy |